Chiou, Shene
Al-Ani, Aysha H
Pan, Yi https://orcid.org/0009-0007-1733-3759
Patel, Komal M
Kong, Isabella Y
Whitehead, Lachlan W
Light, Amanda
Young, Samuel N
Barrios, Marilou
Sargeant, Callum
Rajasekhar, Pradeep https://orcid.org/0000-0002-1983-7244
Zhu, Leah https://orcid.org/0009-0002-6842-8591
Hempel, Anne
Lin, Ann
Rickard, James A
Hall, Cathrine
Gangatirkar, Pradnya
Yip, Raymond KH https://orcid.org/0000-0003-2698-7686
Cawthorne, Wayne https://orcid.org/0009-0001-8467-8091
Jacobsen, Annette V https://orcid.org/0000-0003-0252-7685
Horne, Christopher R
Martin, Katherine R https://orcid.org/0000-0001-9453-9573
Ioannidis, Lisa J https://orcid.org/0000-0003-1287-7347
Hansen, Diana S https://orcid.org/0000-0003-4511-7918
Day, Jessica
Wicks, Ian P
Law, Charity
Ritchie, Matthew E
Bowden, Rory
Hildebrand, Joanne M https://orcid.org/0000-0002-1456-2042
O’Reilly, Lorraine A https://orcid.org/0000-0001-7134-6496
Silke, John https://orcid.org/0000-0002-7611-5774
Giulino-Roth, Lisa
Tsui, Ellen https://orcid.org/0009-0005-7340-7412
Rogers, Kelly L
Hawkins, Edwin D
Christensen, Britt
Murphy, James M https://orcid.org/0000-0003-0195-3949
Samson, André L https://orcid.org/0000-0002-0637-2716
Funding for this research was provided by:
DHAC | National Health and Medical Research Council (1172929)
DHAC | National Health and Medical Research Council (2008652)
DHAC | National Health and Medical Research Council (2002965)
DHAC | National Health and Medical Research Council (9000719)
Kenneth Rainin Foundation
Avant Foundation
Crohn’s and Colitis Australia
University of Melbourne
Article History
Received: 8 November 2023
Revised: 19 April 2024
Accepted: 22 April 2024
First Online: 15 May 2024
Disclosure and competing interests statement
: KMP, SNY, AH, AL, PG, CRH, JD, IPW, JMH, JS, JMM, and ALS have contributed to the development of necroptosis pathway inhibitors in collaboration with Anaxis Pharma Pty Ltd. YP is a co-holder of patent for material arising from this study. All other authors have no additional financial interests.